Windtree Therapeutics Inc (WINT) concluded trading on Wednesday at a closing price of $0.24, with 22.41 million shares of worth about $5.38 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -93.45% during that period and on January 15, 2025 the price saw a loss of about -2.76%. Currently the company’s common shares owned by public are about 11.05M shares, out of which, 10.99M shares are available for trading.
Stock saw a price change of -19.59% in past 5 days and over the past one month there was a price change of -32.50%. Year-to-date (YTD), WINT shares are showing a performance of -30.43% which decreased to -97.64% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.24 but also hit the highest price of $14.75 during that period. The average intraday trading volume for Windtree Therapeutics Inc shares is 2.20 million. The stock is currently trading -22.10% below its 20-day simple moving average (SMA20), while that difference is down -43.85% for SMA50 and it goes to -93.30% lower than SMA200.
Windtree Therapeutics Inc (NASDAQ: WINT) currently have 11.05M outstanding shares and institutions hold larger chunk of about 1.48% of that.
The stock has a current market capitalization of $2.68M and its 3Y-monthly beta is at 0.60. It has posted earnings per share of -$18.63 in the same period. It has Quick Ratio of 0.27 while making debt-to-equity ratio of 1.68. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for WINT, volatility over the week remained 13.86% while standing at 11.92% over the month.
Stock’s fiscal year EPS is expected to rise by 94.00% while it is estimated to increase by 49.47% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Ladenburg Thalmann on June 26, 2020 offering a Buy rating for the stock and assigned a target price of $12.25 to it.
